• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a method for preparing a faecal microbiota sample from a donor subject, comprising the steps of: a) collecting at least one faecal microbiota sample from the donor subject, and less than 5 minutes after sampling, placing said sample obtained in a) in an oxygen-tight collection device, c) mixing the sample obtained in b) with at least one aqueous saline solution comprising at least one cryoprotectant and / or a filler, d) optionally, the filtration of the mixture obtained in c), in particular by a filter comprising pores with a diameter less than or equal to 0.7 mm, preferably less than or equal to 0.5 mm, and e) storing the mixture obtained in c) or d) by freezing at a temperature between -15 ° C and -100 ° C, the steps b) to e) being performed anaerobically.
    公开号:FR3035328A1
    申请号:FR1553716
    申请日:2015-04-24
    公开日:2016-10-28
    发明作者:Herve Affagard；Carole Schwintner；Catherine Juste；Joel Dore；Patricia Lepage；Christel Maillet；Sylvie Rabot；Fernanda Fonseca；Herve Blottiere
    申请人:Institut National de la Recherche Agronomique INRA；Maat Pharma SA；
    IPC主号:
    专利说明:

    [0001] The present invention relates to a method for preparing a sample of fecal microbiota. The invention also relates to the use of said sample in the transplantation of fecal microbiota, preferably for treating intestinal dysbiosis, particularly Clostridium difficile infections. The human intestinal microbiota is the set of micro-organisms (bacteria, yeasts and fungi) found in the human gastrointestinal system (stomach, intestine and colon). The microbial diversity is currently estimated at about 103 bacterial species making up the dominant intestinal microbiota of an adult, with an abundance of 1014 bacteria, representing a bacterial metagenome of 200,000 to 800,000 genes in each individual, ie 10 at 50 times the number of genes in the human genome.
    [0002] Sterile in utero, the intestine colonizes from the first days of life until evolving towards a single individual microbiota. Each person has relatively similar bacteria in terms of species, but the exact composition of its microbiota (species, proportions) is largely (more than% of species) specific to the host. Thus, the human intestinal microbiota is a very diverse ecosystem, complex and specific to each individual. It is essential for the health of an individual to maintain a stable microbiota that is both able to return to its original state after a change and resistant to invasion. Maintaining a great diversity of the microbiota promotes its stability. However, certain pathologies or treatments unbalance the microbiota: antibiotics for example, as well as inflammatory component diseases, such as chronic inflammatory bowel disease (IBD), may limit the diversity of the microbiota in the intestine. Antibiotic treatments (or antibiotics), in particular, result in an alteration of the microbiota, which can promote the proliferation of pathogenic organisms such as Clostridium difficile.
    [0003] 3035328 2 Clostridium difficile infections are responsible for nosocomial diarrhea; this bacterium is resistant to conventional antibiotics (broad spectrum, such as vancomycin or metronidazole). In order to restore the intestinal microbiota, and to fight against Clostridium difficile infections, and thereby restore homeostasis (i.e., symbiosis), fecal microbiota transplantation is contemplated and tested. It consists of introducing the stool of a healthy donor into the gastrointestinal tract of a recipient patient to rebalance the altered intestinal microbiota of the host. This fecal microbiota transplantation can be allogeneic (that is, from a healthy individual donor to a patient) or autologous (that is, from an individual to himself).
    [0004] The results obtained on Clostridium difficile infections are encouraging, and some patients have been successfully treated (Tauxe et al, Lab Medicine, Winter 2015, Volume 46, Number 1). However, the current transplantation method is empirical and takes no particular precautions to best preserve the viability of anaerobic bacteria, the major components of the gut microbiota. In addition, the efficiency of fecal microbiota transplantation is variable, and may require more than one cure. In addition, allogeneic transplantation requires testing the donor's faeces to ensure that no pathogenic germ will be transplanted to the recipient, or will present a risk to personnel handling it during the operation. There is therefore a need for a fecal microbiota transplantation process that is secure, effective and easy to implement, especially on an industrial scale. In addition, there is a need for a fecal microbiota transplantation method in which the viability of the bacteria is maintained. The present invention makes it possible to meet these needs. The present invention thus relates to a method for preparing a faecal microbiota sample from a donor subject, comprising the steps of: a) taking at least one faecal microbiota sample from the donor subject, 3035328 3b ) within a period of less than 5 minutes after sampling, placing the sample obtained in (a) in an oxygen-tight collection device, (c) mixing the sample obtained in (b) with at least one aqueous saline solution comprising at least one cryoprotectant and / or a filler, d) optionally, the filtration of the mixture obtained in c), in particular by a filter comprising pores with a diameter of less than or equal to 0.7 mm, preferably less than or equal to 0.5 mm and e) storage of the mixture obtained in c) or d) by freezing at a temperature between -15 ° C and -100 ° C, preferably between -60 ° C and -90 ° C, steps b) e) being carried out anaerobically. Such a fecal microbiota transplantation method is indeed easy to implement, and its effectiveness can be estimated by comparing the microbial population obtained after the process, compared to the initial sample. Different indices can be used to evaluate this efficiency, and the following results could be obtained: 15 Indices Dissimilarity Distance Index Divergence Index Coefficient of Bray- Jensen- correlation of Curtis Canberra Jaccard Shannon Morisita Pearson Family <0 , 4 <0.7 <0.6 <0.4 <0.5> 0.7 Genus <0.5 <0.7 <0.7 <0.4 <0.6> 0.5 OTU <0 The present invention also relates to the use of a fecal microbiota sample from a donor subject that can be obtained by the method according to the invention, in the thawed state, in autologous or allogenic fecal microbiota transplantation. The present invention also relates to the use of a fecal microbiota sample of a donor subject that can be obtained by the process according to the invention, in the thawed state, for treating intestinal dysbiosis, and in particular the Clostridium difficile infections, dysbiosis induced by drug treatments, by physical treatments (radiation in particular), by surgical interventions (intestinal in particular), or by nutritional contributions. The present invention also relates to the use of a fecal microbiota sample of a donor subject that can be obtained by the process according to the invention, in the thawed state, to treat a pathology chosen from the inflammatory bowel diseases (IBD), intestinal functional disorders, obesity, metabolic diseases (type 2 diabetes, metabolic syndrome in particular) and autoimmune diseases (type 1 diabetes in particular), allergies, liver diseases (steatosis, cirrhosis in particular), certain neurological diseases (especially autism) and certain cancers (colorectal cancer in particular). By intestinal dysbiosis, we mean any sustained imbalance of the gut microbiota. Sustained imbalance of the gut microbiota is understood to mean any loss of beneficial microorganisms, and / or any loss of microorganism diversity, and / or any expansion or development of aggressive microorganisms among commensals (pathobionts), and / or any proliferation of pathogenic microorganisms (C. difficile in particular). Any sustained alteration of the human intestinal microbiota can indeed cause a pathological state. In particular, the reduction of diversity within the microbiota is characteristic of diseases associated with dysbiosis (obesity, Crohn's disease, diabetes or allergy in particular) (Sansonetti, Collège de France, January 22, 2014). Preferably, the pathology to be treated is intestinal dysbiosis. Inflammatory chronic diseases of the intestine (IBD) is understood to mean, in particular, Crohn's disease, ulcerative colitis. Functional bowel disorders include irritable bowel syndrome, spasmodic colitis. The method of preparing a faecal microbiota sample of a donor subject according to the invention thus comprises a step a) of sampling at least one faecal microbiota sample from the donor subject. This step is preferably done by taking a stool sample from the donor subject. Indeed, the stool sample contains fecal microbiota of the donor subject. Thus, the method according to the invention comprises a step a) of sampling at least one stool sample, comprising the fecal microbiota, from the donor subject.
    [0005] Preferably, according to the invention, the donor subject is a healthy human subject. By "healthy" subject, we mean a subject not suffering from an imbalance of the intestinal microbiota or a pathology diagnosed / recognized by the medical profession. Preferably, the stool sample has a mass of at least 20 g.
    [0006] Following this sampling step, and in a very short time, ie less than 5 minutes after the sampling, preferably less than 3 minutes, more preferably less than 1 minute, the sample obtained in a) is placed in a sampling device. oxygen-tight collection: this is step b).
    [0007] The rest of the process is now performed anaerobically (i.e. in anaerobic atmosphere). Preferably, the airtight collection device is in a form of the type comprising: a container comprising a body which has an interior space adapted to receive the fecal microbiota sample from the donor subject, and a neck which defines an access opening to the interior space of the body, and - a cover adapted to be removably and sealingly mounted on the neck of the container so as to close the access opening of the neck and to close the space The interior of the body, wherein the body of the container consists of a flexible bag, and wherein at least one of the container and the lid is provided with an evacuation member adapted to evacuate at least a portion of the gases contained in the interior space of the container body.
    [0008] Preferably, the device discharge member includes a passageway through one of the container and the lid, and a closure member of the passage to prevent external fluids from entering the interior space of the container. container body. Preferably, the device discharge member further comprises a microporous filtration membrane disposed in the passage.
    [0009] Alternatively, the airtight collection device is in a form of the type comprising: a container comprising a body having an interior space adapted to receive the fecal microbiota sample from the donor subject, and a neck which defines an access opening to the interior space of the body, and - a cover adapted to be removably and sealingly mounted on the neck 5 of the container so as to close the access opening of the neck and to close the door. interior space of the body, wherein the interior space of the container body optionally comprises a chemical device that neutralizes oxygen. Preferably, the airtight collection device is used for steps a) and b): the sampling of the sample of step a) takes place directly in said device, in particular in the container, and closing the device, in particular by means of the lid, places the sample in an oxygen-free atmosphere (step b). According to the process of the invention, steps b) to e) are carried out under an atmosphere free of oxygen. In anaerobiosis, the viability of the bacteria constituting the fecal microbiota present in the sample is thus preserved. In particular, the device used in step b), mentioned above, makes it possible to perform all the steps b) to e) under anaerobic conditions.
    [0010] Once the sample (obtained in a) is placed in an oxygen-tight collection device, it may optionally be incubated at a temperature of between 33 ° C. and 40 ° C. for a maximum duration of 75 hours. . Preferably, this incubation step is carried out at a temperature between 35 ° C and 38 ° C for a period of between 24 and 73 hours. Ideally, this step is at a temperature of about 37 ° C for 72 hours. Alternatively, the sample may, optionally, be incubated at a temperature between 2 ° C and 10 ° C for a maximum of 75h. Preferably, this incubation step is carried out at a temperature between 4 ° C and 8 ° C, for a period of between 24 and 72 hours. At the end of this step, a visual check can be made to evaluate the quality of the sample obtained at this stage of the process. If this check is compliant, optionally, a transport step can take place. This transport step makes it possible to repatriate the sample from the sampling site to the laboratory for further processing and analysis. The aforementioned visual inspection can also be carried out after the transport. Thus, preferably, the sample placed in the collection device of step b) undergoes a transport step before step c). Also preferably, the sample placed in the collection device of step b) is incubated at a temperature of between 33 ° C. and 40 ° C., preferably between 35 ° C. and 38 ° C., for a maximum duration of 75h, preferably between 24h and 73h, between steps b) and c). Preferably, the incubation takes place before and during the transport step. Then step c): this step comprises mixing the sample obtained in b) with at least one aqueous saline solution comprising at least one cryoprotectant and / or a filler.
    [0011] If a transport step, and possibly an incubation step, take place, then step c) obviously comprises mixing the sample obtained in b), after transport and / or incubation, with at least one solution. saline aqueous composition comprising at least one cryoprotectant and / or a filler.
    [0012] Typically, the aqueous salt solution according to the invention comprises water and physiologically acceptable salts. Typically, the salts are calcium, sodium, potassium or magnesium salts, with chloride, gluconate, acetate or hydrogencarbonate ions. The aqueous salt solution according to the invention may also optionally comprise at least one antioxidant. The antioxidant is in particular chosen from ascorbic acid and its salts (ascorbate), tocopherols (especially α-tocopherol), cysteine and its salified forms (hydrochloride in particular) and their mixtures. Preferably, the aqueous salt solution according to the invention comprises: at least one salt chosen from sodium chloride, calcium chloride, magnesium chloride, potassium chloride, sodium gluconate and sodium acetate, and Optionally at least one antioxidant, preferably chosen from sodium L-ascorbate, tocopherols, L-cysteine hydrochloride monohydrate and mixtures thereof. Typically, the salt is present in the aqueous saline solution in a concentration of between 5 and 20 g / l, preferably between 7 and 10 g / l. Typically, the antioxidant is present in the aqueous saline solution in an amount of between 3 and 10% by weight relative to the total volume of solution, preferably in an amount of between 4 and 6% by weight relative to the total volume of solution. Preferably, when the antioxidant is a mixture of sodium L-ascorbate and L-cysteine hydrochloride monohydrate, sodium L-ascorbate is present in an amount of from 4 to 6% by weight based on the total volume of solution, and the L-cysteine hydrochloride monohydrate is present in an amount between 0.01 and 0.1% by weight relative to the total volume of solution.
    [0013] Preferably, the aqueous salt solution according to the invention also comprises at least one cryoprotectant. A cryoprotectant is a substance used to protect the sample from damage caused by freezing, especially due to the formation of ice crystals. Preferably, the cryoprotectant is selected from polyols, di-pentasaccharides (i.e. disaccharides, trisaccharides, quadrisaccharides and pentasaccharides), DMSO and mixtures thereof. Preferably, the cryoprotectant is chosen from polyols, tri- and disaccharides, DMSO and mixtures thereof. More preferably, the cryoprotectant present in the aqueous saline solution is a disaccharide or a trisaccharide.
    [0014] Among the polyols which may be used, glycerol, mannitol, sorbitol, but also propylene glycol or ethylene glycol may be found. Among the di-pentasaccharides which can be used, mention may be made of dimers, trimers, quadrimers and pentamers of identical or different units, said units being chosen from glucose, fructose, galactose, fucose and N-acetylneuraminic acid. . Among the disaccharides that can be used are, in particular, trehalose or one of its analogues, or sucrose.
    [0015] Finally, DMSO, or dimethylsulfoxide, is a conventional cryoprotectant. These cryoprotectants can be used alone or as a mixture. Typically, the total amount of cryoprotectant present in the aqueous saline solution is from 3 to 30% by weight based on the total volume of solution, preferably from 4% to 20% by weight based on the total volume of solution. Preferably, the cryoprotectant is chosen from glycerol, mannitol, sorbitol, DMSO, propylene glycol, ethylene glycol, trehalose and its analogues, sucrose, galactose-lactose and their mixtures. More preferably, the cryoprotectant is galactose-lactose or trehalose.
    [0016] Preferably, the aqueous saline solution according to the invention comprises at least one filler. The bulking agent is preferably selected from partial hydrolysates of starch or starch. Partial hydrolysates of starch, especially wheat or maize, as well as partial hydrolysates of starch, for example potato, comprise a large amount of maltodextrins. Maltodextrins are the result of the partial hydrolysis of starch or starch, and consist of various sugars (glucose, maltose, maltotriose, oligo- and polysaccharides), the proportions of which vary according to the degree of hydrolysis.
    [0017] Preferably, the bulking agent present in the aqueous saline solution is a mixture of maltodextrins, wherein the amount of maltodextrins is between 4 and 20% by weight based on the total volume of solution. Step c) of mixing the sample obtained in b) with at least one aqueous saline solution comprising at least one cryoprotectant can in particular be carried out by kneading, in order to obtain a homogeneous mixture. Preferably, the sample obtained in b) is mixed with said aqueous saline solution in a weight / volume ratio of between 0.5 weight: 10 volumes and 2 weight: 2 volumes. A sample weight / volume ratio: solution equal to 0.5 weight: 10 volumes means that the sample is mixed with 0.5 weight (for example 0.5 g) for 10 volumes of solution (for example 10 ml). Preferably, the weight / volume ratio of the sample: solution is equal to 1 weight of sample per 4 volumes of solution (1 weight: 4 volumes). Once this step has been completed, an optional step d) can be performed. Step d) comprises filtration of the mixture obtained in c), in particular by a filter comprising pores with a diameter of less than or equal to 0.7 mm, preferably less than or equal to 0.5 mm. Such a filtration allows the retention of coarse particles, and the recovery of the bacteria of interest (constitutive of the fecal microbiota) in the filtrate.
    [0018] Then, after step c) or d), when the latter takes place, the mixture obtained is stored by freezing at a temperature between -15 ° C and -100 ° C: this is step e) . Preferably, the freezing (and therefore storage) temperature is between -60 ° C and -90 ° C; more preferably it is about -80 ° C or about -65 ° C.
    [0019] In order to be frozen, following step c) or d), and before step e), the mixture may be aliquoted beforehand to ensure specimens of constant volume. For example, the aliquoting is performed to obtain specimens of volume equal to 50 ml, 100 ml, 150 ml, or 200 ml. Preferably, the aliquoting is performed to obtain specimens of volume equal to 100 ml.
    [0020] This freezing and storage step makes it possible to keep the treated samples for a period of at least 2 months. The samples thus stored also have good quality, even after thawing. Preferably, the process according to the invention comprises a step f) of thawing the frozen sample obtained in e), under anaerobic conditions, to room temperature. This f) defrosting step may be carried out by placing the frozen sample in a water bath at a temperature of between 35 ° C. and 40 ° C., for example 37 ° C., for a duration of a few minutes (typically from 2 to 10 minutes). The thawing step f) can also be carried out by placing the frozen sample at a temperature of between 2 ° C and 10 ° C, for example between 4 ° C and 8 ° C, for a period of 10 to 20 minutes. hours.
    [0021] The sample thus thawed at room temperature can then be administered to the recipient patient. The recipient patient may be different from the donor subject, and the transplant is then allogenic.
    [0022] The recipient patient may also be identical to the donor subject, and the transplantation is then autologous; this type of transplantation can take place when the subject, while healthy, gives a sample before the alteration of its microbiota. The sample is then frozen according to the steps described in the present application, and then transplanted to the same subject (recipient patient) if it has in particular a difficult Clostridium 10 infection. Autologous fecal microbiota transplantation has the advantage of avoiding transmission of pathogen from another donor. The present invention also relates to a fecal microbiota sample of a donor subject obtainable by the process according to the invention for use in the transplantation of autologous or allogenic fecal microbiota. The present invention also relates to a faecal microbiota sample of a donor subject obtainable by the process according to the invention, for its use for treating Clostridium difficile infections. The present invention also relates to a fecal microbiota sample of a donor subject that can be obtained by the process according to the invention, for its use for treating a pathology selected from inflammatory bowel diseases (IBD). ), functional bowel disorders, obesity, metabolic diseases and autoimmune diseases, allergies, neurological diseases and cancers.
    [0023] The invention will now be exemplified with the aid of the following examples, which are not limiting. Example 1: Preparation of a faecal microbiota sample from a donor subject according to the invention and comparison with an aerobic method Materials & Methods: 3035328 12 Sampling For three consecutive days, 3 participants (one per day) are invited to provide a fresh stool sample, collected in the morning and anoberosed with the addition of an Anaerocult® IS type catalyst (ref 116819 from Merck-Millipore) (step a) of the process). A visual assessment and stool qualification are done according to the Bristol chart. Within 2 hours after collection, the stools are placed in a freter chamber with an anaerobic atmosphere, in which they are homogenized for 5 minutes by manual mixing in the collection bag (step b) of the method). Small aliquots (150-200 mg) of crude fecal matter (SB for Brute Saddle) are retained for profiling of 16S rDNA and 16S rRNA of raw faeces. An aliquot (1g) is diluted in cold enriched brain-heart broth, centrifuged at 220,000xg, at 4 ° C for 1hr, and the supernatant is fractionated into 1ml aliquots for metabolomic profiling of raw faecal water. Aliquots for DNA, RNA and metabolomic profiling are stored at -80 ° C. A third aliquot (0.4 g) is diluted in 1.6 ml of the culture broth and used to inoculate 3 Kimax culture tubes (0.5 ml of inoculum per 9.5 ml of broth, extemporaneously enriched in L-ascorbate of sodium and L-cysteine hydrochloride monohydrate at a final concentration of 5% [w / v] and 0.05% [w / v], respectively) for the baseline activity test. Eight stool fractions are then transferred to Stomacher filter bags: 4 bags for conditioning in the four diluents under anaerobic conditions, and four bags for packaging in the same four diluents under aerobic conditions.
    [0024] Conditioning Two teams perform the parallel conditioning steps to ensure that all samples are treated identically. The 4 fractions under each atmosphere condition are resuspended in 4 volumes of the following aqueous solutions (step c) of the method): - 9g / L salt solution (identified as "NaCl"), - 6.25% DMSO (v) / v) in saline 9 g / L (identified as "DMSO"), 3035328 13 - MDX (maltodextrins) 15% (w / v) + TR (trehalose) 5% (w / v) in saline 9g / L (identified as "MDX15"), and - MDX 5% + TR 15% in saline 9g / L (identified as "TRIS"). The anaerobic preparations are further supplemented by the two reducing agents, sodium L-ascorbate and L-cysteine hydrochloride monohydrate, to a final concentration of 5% (w / v) and 0.1% (w / w). v), respectively. Resuspension is provided by manual mixing for 5 minutes through the bag. This mixture provides filtration at the same time, through a gauze (0.5 mm holes) present in the bag (step d) of the process). 20 ml of each filtrate are then pipetted into two CryoMACS ® Freezing Bags 50 freezing bags (Ref Miltenyi Biotec SAS 200-074-400), giving a total of 16 CryoMACS ® for each donor (2 x NaCl-An). , 2 x DMSO-An, 2 x MDX15-An, 2 x TR15-An, 2 x NaCl-Ae, 2 x DMSO-Ae, 2 x MDX15-Ae, 2 x TR15-Ae), which are stored at -80 ° C (step e) of the process).
    [0025] Aliquots of each filtrate are also conserved for 16S rDNA, 16S rRNA, metabolomic profiling, and bacterial cultures. For 16S, 16S rRNA and metabolomic rRNA, 6 1ml aliquots of each suspension are centrifuged at 5000 x g, 4 ° C for 30 minutes; the pooled supernatants are further ultracentrifuged (220,000 xg, 4 ° C, 1 hr) for metabolomics, while the wet 5,000 xg pellet is retained for profiling 16S rDNA and rRNA. 16S. Three 0.5 ml aliquots of each filtrate were used to inoculate 3 culture broth Kimax culture tubes, as previously described for crude faeces. The entire process is repeated 3 times over 3 consecutive days to manage 3 different stools of three different donors. Repackaging To ensure the same storage time for the 3 donor samples, CryoMACS bags are thawed for 3 consecutive days, stool of one person per 30 days. Thawing is carried out according to two different protocols (step f) of the process): - overnight at 4 ° C; For 5 minutes at 37 ° C. in a water bath maintained in a mobile incubator. After thawing, culture and metabolic activity are probed by culture in brain-heart broth. Aliquots of thawed filtrates prior to culture (non-cultured thawed filtrates) are also conserved for 16S rDNA, 16S rRNA, and metabolomic profiling. Microbial cultures At each critical stage of the process, a sample is collected and used to seed triplicate culture tubes each containing 9.5 ml of enriched brain-core broth. The culture tubes had already been reduced in the anaerobic chamber to remove any dissolved oxygen and allow the growth of strict anaerobic bacteria. After incubation for 48 hours at 37 ° C under strict anaerobic conditions, the triplicate cultures are harvested, pooled in Falcon50 tubes, and centrifuged for 30 min at 5000 x g, 4 ° C. The supernatant is further ultracentrifuged for 1 hour at 220,000 xg, 4 ° C for metabolomic profiling (1 ml fraction supernatant stored at -80 ° C), while the wet 5,000 xg pellet is divided into three parts. Equal fractions in Sarstedt tubes for 16S rDNA and 16S rRNA, all aliquots being stored at -80 ° C until analyzes.
    [0026] Metabolomic Analyzes The metabolomic analyzes are then performed to obtain the profiles by LC-MS (Q-Exactive Thermofisher Scientific) methods in the positive and negative ionization modes.
    [0027] Phylogenetic profile Total DNA is extracted. It is then controlled and sequenced by pyrosequencing. Transcriptomic Profiles RNA is extracted using the following method: briefly, the bacteria are lysed by chemical and mechanical treatment; then the lysates are precipitated and centrifuged; Finally, the RNA is isolated and purified on minicolumns using the kit High Pure Isolation Kit (Roche). Their integrity is evaluated and they are then subjected to RT-PCR. The cDNAs are sequenced by pyrosequencing and then subjected to the same analysis as for the DNA.
    权利要求:
    Claims (10)
    [0001]
    REVENDICATIONS1. A method for preparing a faecal microbiota sample from a donor subject, comprising the steps of: a) collecting at least one sample of faecal microbiota from the donor subject, b) within less than 5 minutes of collection , placing said sample obtained in a) in an oxygen-tight collection device, c) mixing the sample obtained in b) with at least one aqueous saline solution comprising at least one cryoprotectant and / or an agent charge, d) optionally, the filtration of the mixture obtained in c), in particular by a filter comprising pores with a diameter less than or equal to 0.7 mm, preferably less than or equal to 0.5 mm, and e) the storage of the mixture obtained in c) or d) by freezing at a temperature between -15 ° C and -100 ° C, preferably between -60 ° C and -90 ° C, steps b) to e) being performed anaerobically.
    [0002]
    2. Method according to claim 1, characterized in that the sample placed in the collection device of step b) undergoes a transport step before step c). 20
    [0003]
    3. Method according to one of claims 1 to 2, characterized in that the sample placed in the collection device of step b) is incubated at a temperature between 33 ° C and 40 ° C for a maximum period 75h between steps b) and c). 25
    [0004]
    4. Method according to one of claims 1 to 3, characterized in that the cryoprotectant is selected from polyols, di- pentasaccharides, DMSO and mixtures thereof.
    [0005]
    5. Method according to one of claims 1 to 4, characterized in that the cryoprotectant is chosen from glycerol, mannitol, sorbitol, DMSO, propylene glycol, ethylene glycol, trehalose, sucrose, galactose-lactose and their mixtures. 3035328 17
    [0006]
    6. Method according to one of claims 1 to 5, characterized in that the aqueous saline solution comprises: - at least one salt selected from sodium chloride, calcium chloride, magnesium chloride, potassium chloride, sodium gluconate and sodium acetate, and optionally at least one antioxidant, preferably selected from sodium L-ascorbate, tocopherols, L-cysteine hydrochloride monohydrate and mixtures thereof.
    [0007]
    7. Method according to one of claims 1 to 6, characterized in that the filler is maltodextrins.
    [0008]
    8. Method according to one of claims 1 to 7, characterized in that it comprises a step f) thawing the frozen sample obtained in e), anaerobically, to room temperature.
    [0009]
    9. Fecal microbiota sample of a donor subject obtainable by the method according to claim 8, for its use in the transplantation of autologous or allogenic fecal microbiota.
    [0010]
    10. Fecal microbiota sample of a donor subject obtainable by the process according to claim 8 for use in treating intestinal dysbiosis.
    类似技术:
    公开号 | 公开日 | 专利标题
    FR3035328B1|2019-08-23|PROCESS FOR PREPARING A MICROBIOTE FECAL SAMPLE
    Nkamga et al.2017|Archaea: Essential inhabitants of the human digestive microbiota
    EP3389679B1|2020-02-12|Method for lyophilisation of a sample of fecal microbiota
    Cao et al.2014|Association between Faecalibacterium prausnitzii reduction and inflammatory bowel disease: a meta-analysis and systematic review of the literature
    EP3389681B1|2020-02-05|Lyophilized composition for preserving microbiota in its ecosystem
    KR20200130367A|2020-11-18|Fecal collection method and sample preparation method for fecal microbiota transplantation
    EP3573631A1|2019-12-04|Fecal microbiota for treating patients undergoing a hematopoietic stem cell transplant
    AU2016252209B2|2022-03-03|Method of preparing a faecal microbiota sample
    He et al.2019|Influence of colonic dialysis using Chinese medicine on creatinine decomposition by intestinal bacteria in uremia rats
    WO2021234102A1|2021-11-25|Decontamination method
    CN110791435A|2020-02-14|Low-temperature cryopreservation preserving fluid
    Mustafa2021|A Study of the Symbiotic Relationship between Prausnitzn Faecalibacterum and Other Colon Species
    Sidorenko et al.2012|Effect of volatile metabolites from germinating seeds on the reproduction of the bacteria Listeria monocytogenes and Yersinia pseudotuberculosis
    Imaizumi et al.2022|Bacterial and eukaryotic communities in pond water of whiteleg shrimp Litopenaeus vannamei and the bacterial communities of their stomach and midgut
    同族专利:
    公开号 | 公开日
    FR3035328B1|2019-08-23|
    JP2018514228A|2018-06-07|
    CA2983192A1|2016-10-27|
    CN107530280A|2018-01-02|
    CN107530280B|2021-10-26|
    AU2016252209A1|2017-12-07|
    EP3285784B1|2020-07-08|
    DK3285784T3|2020-08-24|
    US10980839B2|2021-04-20|
    US20180099012A1|2018-04-12|
    PT3285784T|2020-08-31|
    IL255100D0|2017-12-31|
    ES2812854T3|2021-03-18|
    EP3285784A1|2018-02-28|
    HUE050430T2|2020-12-28|
    JP6858747B2|2021-04-14|
    PL3285784T3|2020-11-16|
    US20210154239A1|2021-05-27|
    WO2016170285A1|2016-10-27|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2012122478A1|2011-03-09|2012-09-13|Regents Of The University Of Minnesota|Compositions and methods for transplantation of colon microbiota|
    US20140363398A1|2013-06-05|2014-12-11|Rebiotix, Inc.|Microbiota restoration therapy , compositions and methods of manufacture|
    US20150037285A1|2013-07-03|2015-02-05|New York University|Methods for efficient transfer of viable and bioactive microbiota|
    AUPQ899700A0|2000-07-25|2000-08-17|Borody, Thomas Julius|Probiotic recolonisation therapy|
    KR20100088894A|2009-02-02|2010-08-11|에이엠바이오 |Methods for producing lactic acid bacteria in a high yield using membrane bioreactor and producing freezing-dried powder of lactic acid bacteria|
    CN102414310B|2009-04-30|2015-05-06|阿克图杰尼斯公司|Cryoprotectants for freeze drying of lactic acid bacteria|
    DK2435554T3|2009-05-26|2017-10-30|Advanced Bionutrition Corp|STABLE DRY POWDER COMPOSITION WITH BIOLOGICALLY ACTIVE MICRO-ORGANISMS AND / OR BIOACTIVE MATERIALS AND PROCEDURES FOR ITS PREPARATION|
    US7888062B1|2010-02-01|2011-02-15|Microbios, Inc.|Process and composition for the manufacture of a microbial-based product|
    WO2011122949A1|2010-04-02|2011-10-06|Antonius Henricus Petrus Bosch|Auxiliary device for receiving fecal matter|
    RU2013109251A|2010-08-04|2014-09-10|Томас Джулиус БОРОДИ|COMPOSITIONS FOR TRANSPLANTATION OF FEKAL FLORA AND METHODS FOR THEIR RECEIVING AND APPLICATION AND DEVICES FOR THEIR DELIVERY|
    CN103160489B|2011-12-12|2015-01-14|润盈生物工程（上海）有限公司|Preparation method and application of daily chemical microencapsulated probiotic|
    WO2014029758A1|2012-08-20|2014-02-27|Chr. Hansen A/S|Method for optimizing a process for freeze drying a bacteria-containing concentrate|
    CN102827796B|2012-09-03|2013-10-30|江南大学|Lactobacillus plantarum with cadmium removing function and usage thereof|
    CA2896795A1|2012-11-26|2014-05-30|Thomas Julius Borody|Compositions for the restoration of a fecal microbiota and methods for making and using them|
    CN110917220A|2013-02-04|2020-03-27|赛里斯治疗公司|Therapeutic compositions and methods of use thereof|
    US10973861B2|2013-02-04|2021-04-13|Seres Therapeutics, Inc.|Compositions and methods|
    WO2014152484A1|2013-03-14|2014-09-25|Regents Of The University Of Minnesota|Freeze dried fecal microbiota for use in fecal microbial transplantation|
    EP2991649B1|2013-04-30|2020-06-03|Thomas Julius Borody|Compositions for treating obsessive-compulsive disorder|
    KR102066242B1|2015-06-09|2020-01-14|리바이오틱스, 인코퍼레이티드|Microbial Restoration Therapy Compositions and Methods of Preparation|
    WO2017075098A1|2015-10-26|2017-05-04|Crestovo Llc|Compositions and methods for fecal microbiota-related therapy|FR3045384B1|2015-12-18|2020-02-07|Institut National De La Recherche Agronomique|LYOPHILIZED COMPOSITION FOR THE PRESERVATION OF MICROBIOTE IN ITS ECOSYSTEM|
    US20180030403A1|2016-07-28|2018-02-01|Bobban Subhadra|Devices, systems and methods for the production of humanized gut commensal microbiota|
    FR3062063B1|2017-01-26|2019-04-19|Centre National De La Recherche Scientifique|MICROBIOTE FECAL FOR TREATING PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT|
    EP3485879A1|2017-11-17|2019-05-22|Maat Pharma|Pharmaceutical oral formulation comrpsing bacteria|
    FR3078627B1|2018-03-09|2020-11-13|Maat Pharma|PROCEDURE FOR COLLECTING STOOL AND PROCEDURE FOR PREPARING A SAMPLE FOR TRANSPLANTATION OF FECAL MICROBIOTE|
    EP3597202A1|2018-07-20|2020-01-22|Maat Pharma|Fecal microbiota composition, for use in reducing treatment-induced inflammation|
    CN109010380A|2018-08-21|2018-12-18|卓源健康科技有限公司|A kind of technique that caprophyl transplants the intestinal flora preparation in clinical treatment|
    EP3895716A1|2020-04-17|2021-10-20|Maat Pharma|Fmt performance prediction test to guide and optimize therapeutic management of gvhd patients|
    RU2745125C1|2020-07-15|2021-03-22|Общество с ограниченной ответственностью «Байкальский центр биомедицинских исследований» |Device and the method for preparation in anaerobic conditions of donor fecal microbiota for transplantation|
    CN112226369A|2020-10-23|2021-01-15|重庆浦洛通基因医学研究院有限公司|Intestinal flora preservation solution and preparation method thereof|
    RU2761047C1|2021-03-10|2021-12-02|Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии"|Device for preparing donor fecal material for transplantation|
    法律状态:
    2016-04-27| PLFP| Fee payment|Year of fee payment: 2 |
    2016-10-28| PLSC| Publication of the preliminary search report|Effective date: 20161028 |
    2017-03-29| PLFP| Fee payment|Year of fee payment: 3 |
    2018-02-27| PLFP| Fee payment|Year of fee payment: 4 |
    2019-02-08| PLFP| Fee payment|Year of fee payment: 5 |
    2020-02-26| PLFP| Fee payment|Year of fee payment: 6 |
    2020-12-11| CD| Change of name or company name|Owner name: INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULT, FR Effective date: 20201103 Owner name: MAAT PHARMA, FR Effective date: 20201103 |
    2021-07-28| PLFP| Fee payment|Year of fee payment: 7 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1553716|2015-04-24|
    FR1553716A|FR3035328B1|2015-04-24|2015-04-24|PROCESS FOR PREPARING A MICROBIOTE FECAL SAMPLE|FR1553716A| FR3035328B1|2015-04-24|2015-04-24|PROCESS FOR PREPARING A MICROBIOTE FECAL SAMPLE|
    EP16723433.5A| EP3285784B1|2015-04-24|2016-04-22|Method for preparing a fecal microbiota sample|
    PL16723433T| PL3285784T3|2015-04-24|2016-04-22|Method for preparing a fecal microbiota sample|
    US15/568,838| US10980839B2|2015-04-24|2016-04-22|Method of preparing a faecal microbiota sample|
    PT167234335T| PT3285784T|2015-04-24|2016-04-22|Method for preparing a fecal microbiota sample|
    ES16723433T| ES2812854T3|2015-04-24|2016-04-22|Procedure for preparing a fecal microbiota sample|
    CA2983192A| CA2983192A1|2015-04-24|2016-04-22|Method for preparing a fecal microbiota sample|
    CN201680023630.8A| CN107530280B|2015-04-24|2016-04-22|Preparation method of fecal microbiota sample|
    HUE16723433A| HUE050430T2|2015-04-24|2016-04-22|Method for preparing a fecal microbiota sample|
    PCT/FR2016/050958| WO2016170285A1|2015-04-24|2016-04-22|Method for preparing a fecal microbiota sample|
    AU2016252209A| AU2016252209B2|2015-04-24|2016-04-22|Method of preparing a faecal microbiota sample|
    DK16723433.5T| DK3285784T3|2015-04-24|2016-04-22|Method for preparing a sample of fecal microbiota|
    JP2018506488A| JP6858747B2|2015-04-24|2016-04-22|How to prepare a fecal microbiota sample|
    IL255100A| IL255100D0|2015-04-24|2017-10-17|Method of preparing a faecal microbiota sample|
    US17/167,573| US20210154239A1|2015-04-24|2021-02-04|Method of preparing a faecal microbiota sample|
    [返回顶部]